Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65


A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept.

Mertins SD, Scudiero DA, Hollingshead MG, Divelbiss RD Jr, Alley MC, Monks A, Covell DG, Hite KM, Salomon DS, Niederhuber JE.

PLoS One. 2013;8(2):e57099. doi: 10.1371/journal.pone.0057099. Epub 2013 Feb 21.


Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma.

Saini V, Hose CD, Monks A, Nagashima K, Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, Burkett MW, Delosh RM, Silvers TE, Scudiero DA, Shoemaker RH.

PLoS One. 2012;7(8):e41401. doi: 10.1371/journal.pone.0041401. Epub 2012 Aug 3. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/8c74aaee-897d-4682-b62d-d95a3506c210.


Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.

Klausmeyer P, McCloud TG, Scudiero DA, Currens MJ, Cardellina Ii JH, Shoemaker RH.

Bioorg Med Chem. 2012 Aug 1;20(15):4646-52. doi: 10.1016/j.bmc.2012.06.017. Epub 2012 Jun 16.


Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cells.

Stein U, Fleuter C, Siegel F, Smith J, Kopacek A, Scudiero DA, Hite KM, Schlag PM, Shoemaker RH, Walther W.

Br J Cancer. 2012 Apr 10;106(8):1395-405. doi: 10.1038/bjc.2012.81. Epub 2012 Mar 29.


Cysteine 81 is critical for the interaction of S100A4 and myosin-IIA.

Dulyaninova NG, Hite KM, Zencheck WD, Scudiero DA, Almo SC, Shoemaker RH, Bresnick AR.

Biochemistry. 2011 Aug 23;50(33):7218-27. doi: 10.1021/bi200853y. Epub 2011 Jul 21.


Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel.

Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW, Hite KM, Alley M, Hollingshead M, Shoemaker RH, Niederhuber JE.

Stem Cells. 2010 Apr;28(4):649-60. doi: 10.1002/stem.324.


RSK2 Binding Models Delineate Key Features for Activity.

Gussio R, Currens MJ, Scudiero DA, Smith JA, Lannigan DA, Shoemaker RH, Zaharevitz DW, Nguyen TL.

J Chem Pharm Res. 2010;2(5):587-598.


Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.

Klausmeyer P, Zhou Q, Scudiero DA, Uranchimeg B, Melillo G, Cardellina JH, Shoemaker RH, Chang CJ, McCloud TG.

J Nat Prod. 2009 May 22;72(5):805-12. doi: 10.1021/np8006342.


Inhibitors of the NF-kappaB activation pathway from Cryptocarya rugulosa.

Meragelman TL, Scudiero DA, Davis RE, Staudt LM, McCloud TG, Cardellina JH 2nd, Shoemaker RH.

J Nat Prod. 2009 Mar 27;72(3):336-9. doi: 10.1021/np800350x.


Separation and SAR study of HIF-1alpha inhibitory tubulosines from Alangium cf. longiflorum.

Klausmeyer P, McCloud TG, Uranchimeg B, Melillo G, Scudiero DA, Cardellina JH 2nd, Shoemaker RH.

Planta Med. 2008 Feb;74(3):258-63. doi: 10.1055/s-2008-1034315. Epub 2008 Feb 26.


Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen.

Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, Ahn J, Reimers M, Chen Y, Scudiero DA, Weinstein JN, Trent JM, Bittner ML, Meltzer PS, Fornace AJ Jr.

Cancer Res. 2008 Jan 15;68(2):415-24. doi: 10.1158/0008-5472.CAN-07-2120.


Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study.

Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, Cossman J, Kaldjian EP, Scudiero DA, Petricoin E, Liotta L, Lee JK, Weinstein JN.

Mol Cancer Ther. 2007 Mar;6(3):820-32. Epub 2007 Mar 5.


Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells.

Li L, Yang L, Scudiero DA, Miller SA, Yu ZX, Stukenberg PT, Shoemaker RH, Kotin RM.

Gene Ther. 2007 May;14(10):814-27. Epub 2007 Mar 1.


Identification of a new natural camptothecin analogue in targeted screening for HIF-1alpha inhibitors.

Klausmeyer P, McCloud TG, Melillo G, Scudiero DA, Cardellina JH 2nd, Shoemaker RH.

Planta Med. 2007 Jan;73(1):49-52.


Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells.

Reinhold WC, Reimers MA, Maunakea AK, Kim S, Lababidi S, Scherf U, Shankavaram UT, Ziegler MS, Stewart C, Kouros-Mehr H, Cui H, Dolginow D, Scudiero DA, Pommier YG, Munroe DJ, Feinberg AP, Weinstein JN.

Mol Cancer Ther. 2007 Feb;6(2):391-403. Epub 2007 Feb 1.


Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore.

Nguyen TL, Gussio R, Smith JA, Lannigan DA, Hecht SM, Scudiero DA, Shoemaker RH, Zaharevitz DW.

Bioorg Med Chem. 2006 Sep 1;14(17):6097-105. Epub 2006 May 24.


Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.

Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, Gwadry F, Ajay, Kouros-Mehr H, Fridlyand J, Jain A, Collins C, Nishizuka S, Tonon G, Roschke A, Gehlhaus K, Kirsch I, Scudiero DA, Gray JW, Weinstein JN.

Mol Cancer Ther. 2006 Apr;5(4):853-67.


Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries.

Kolonin MG, Bover L, Sun J, Zurita AJ, Do KA, Lahdenranta J, Cardó-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA, Souza GR, Staquicini FI, Kunyiasu A, Scudiero DA, Holbeck SL, Sausville EA, Arap W, Pasqualini R.

Cancer Res. 2006 Jan 1;66(1):34-40.


Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.

Jensen LH, Thougaard AV, Grauslund M, Søkilde B, Carstensen EV, Dvinge HK, Scudiero DA, Jensen PB, Shoemaker RH, Sehested M.

Cancer Res. 2005 Aug 15;65(16):7470-7.


Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel.

Svingen PA, Loegering D, Rodriquez J, Meng XW, Mesner PW Jr, Holbeck S, Monks A, Krajewski S, Scudiero DA, Sausville EA, Reed JC, Lazebnik YA, Kaufmann SH.

Clin Cancer Res. 2004 Oct 15;10(20):6807-20.


Karyotypic complexity of the NCI-60 drug-screening panel.

Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Scudiero DA, Weinstein JN, Kirsch IR.

Cancer Res. 2003 Dec 15;63(24):8634-47.


Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling.

Nishizuka S, Chen ST, Gwadry FG, Alexander J, Major SM, Scherf U, Reinhold WC, Waltham M, Charboneau L, Young L, Bussey KJ, Kim S, Lababidi S, Lee JK, Pittaluga S, Scudiero DA, Sausville EA, Munson PJ, Petricoin EF 3rd, Liotta LA, Hewitt SM, Raffeld M, Weinstein JN.

Cancer Res. 2003 Sep 1;63(17):5243-50.


A high-throughput screen for identification of molecular mimics of Smac/DIABLO utilizing a fluorescence polarization assay.

Glover CJ, Hite K, DeLosh R, Scudiero DA, Fivash MJ, Smith LR, Fisher RJ, Wu JW, Shi Y, Kipp RA, McLendon GL, Sausville EA, Shoemaker RH.

Anal Biochem. 2003 Sep 15;320(2):157-69.


Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines.

Chen ZP, Malapetsa A, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Panasci LC.

Ai Zheng. 2002 Mar;21(3):233-9.


Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.

Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, Melillo G.

Cancer Res. 2002 Aug 1;62(15):4316-24.


DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program.

Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Aloyz R, Panasci LC.

Anticancer Drugs. 2002 Jun;13(5):511-9.


Application of high-throughput, molecular-targeted screening to anticancer drug discovery.

Shoemaker RH, Scudiero DA, Melillo G, Currens MJ, Monks AP, Rabow AA, Covell DG, Sausville EA.

Curr Top Med Chem. 2002 Mar;2(3):229-46. Review.


Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer.

Meinhold-Heerlein I, Stenner-Liewen F, Liewen H, Kitada S, Krajewska M, Krajewski S, Zapata JM, Monks A, Scudiero DA, Bauknecht T, Reed JC.

Am J Pathol. 2001 Apr;158(4):1335-44.


P450 enzyme expression patterns in the NCI human tumor cell line panel.

Yu LJ, Matias J, Scudiero DA, Hite KM, Monks A, Sausville EA, Waxman DJ.

Drug Metab Dispos. 2001 Mar;29(3):304-12.


Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.

Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M, Reed JC.

Clin Cancer Res. 2000 May;6(5):1796-803.


A gene expression database for the molecular pharmacology of cancer.

Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN.

Nat Genet. 2000 Mar;24(3):236-44.


IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.

Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC.

Cancer Res. 1998 Dec 1;58(23):5315-20.


Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen.

Scudiero DA, Monks A, Sausville EA.

J Natl Cancer Inst. 1998 Jun 3;90(11):862. No abstract available.


The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.

Monks A, Scudiero DA, Johnson GS, Paull KD, Sausville EA.

Anticancer Drug Des. 1997 Oct;12(7):533-41. Review. No abstract available.


Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.

O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW.

Cancer Res. 1997 Oct 1;57(19):4285-300.


A protein expression database for the molecular pharmacology of cancer.

Myers TG, Anderson NL, Waltham M, Li G, Buolamwini JK, Scudiero DA, Paull KD, Sausville EA, Weinstein JN.

Electrophoresis. 1997 Mar-Apr;18(3-4):647-53.


An information-intensive approach to the molecular pharmacology of cancer.

Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD.

Science. 1997 Jan 17;275(5298):343-9.


An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines.

Bae I, Smith ML, Sheikh MS, Zhan Q, Scudiero DA, Friend SH, O'Connor PM, Fornace AJ Jr.

Cancer Res. 1996 Feb 15;56(4):840-7.


Bisimidazoacridones and related compounds: new antineoplastic agents with high selectivity against colon tumors.

Cholody WM, Hernandez L, Hassner L, Scudiero DA, Djurickovic DB, Michejda CJ.

J Med Chem. 1995 Aug 4;38(16):3043-52.


Neural computing in cancer drug development: predicting mechanism of action.

Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV, Monks AP, Scudiero DA, Welch L, Koutsoukos AD, Chiausa AJ, et al.

Science. 1992 Oct 16;258(5081):447-51.


Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.

Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, Paull KD, Koutsoukos AD, Rubinstein LV, Boyd MR, et al.

Cancer Res. 1992 Jun 1;52(11):3029-34.


The sensitivities of SV40-transformed human fibroblasts to monofunctional and DNA-crosslinking alkylating agents.

Miyakoshi J, Scudiero DA, Allalunis-Turner J, Day RS 3rd.

Mutat Res. 1991 Jan;254(1):55-64.


1,3-Dialkyl-3-acyltriazenes, a novel class of antineoplastic alkylating agents.

Smith RH Jr, Scudiero DA, Michejda CJ.

J Med Chem. 1990 Sep;33(9):2579-83.


Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.

Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR.

J Natl Cancer Inst. 1990 Jul 4;82(13):1113-8.


Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR.

J Natl Cancer Inst. 1989 Jul 19;81(14):1088-92.


Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.

Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR.

Cancer Res. 1988 Sep 1;48(17):4827-33.


Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR.

Cancer Res. 1988 Feb 1;48(3):589-601.


Development of human tumor cell line panels for use in disease-oriented drug screening.

Shoemaker RH, Monks A, Alley MC, Scudiero DA, Fine DL, McLemore TL, Abbott BJ, Paull KD, Mayo JG, Boyd MR.

Prog Clin Biol Res. 1988;276:265-86. Review. No abstract available.


The role of O6-methylguanine in human cell killing, sister chromatid exchange induction and mutagenesis: a review.

Day RS 3rd, Babich MA, Yarosh DB, Scudiero DA.

J Cell Sci Suppl. 1987;6:333-53. Review.


Alzheimer disease fibroblasts are hypersensitive to the lethal effects of a DNA-damaging chemical.

Scudiero DA, Polinsky RJ, Brumback RA, Tarone RE, Nee LE, Robbins JH.

Mutat Res. 1986 Jan-Feb;159(1-2):125-31.


Supplemental Content

Loading ...
Support Center